WO2001060404A3 - Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens - Google Patents
Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens Download PDFInfo
- Publication number
- WO2001060404A3 WO2001060404A3 PCT/EP2001/001673 EP0101673W WO0160404A3 WO 2001060404 A3 WO2001060404 A3 WO 2001060404A3 EP 0101673 W EP0101673 W EP 0101673W WO 0160404 A3 WO0160404 A3 WO 0160404A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pseudomonas
- oprl
- heterologous antigens
- natural adjuvant
- inducing natural
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 102000004895 Lipoproteins Human genes 0.000 title abstract 2
- 108090001030 Lipoproteins Proteins 0.000 title abstract 2
- 241000589516 Pseudomonas Species 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 101150012056 OPRL1 gene Proteins 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/824—Bacterial vaccine for ovine species, e.g. sheep
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/829—Bacterial vaccine for equine species, e.g. horses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002400495A CA2400495A1 (en) | 2000-02-18 | 2001-02-13 | Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens |
DE60132427T DE60132427D1 (en) | 2000-02-18 | 2001-02-13 | USE OF OPRI LIPOPROTEIN FROM PSEUDOMONAS AS TH1 INDUCING NATURAL ADJUVANT FOR HETEROLOGIST ANTIGENE |
EP01921281A EP1255562B1 (en) | 2000-02-18 | 2001-02-13 | Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens |
AU2001248314A AU2001248314B2 (en) | 2000-02-18 | 2001-02-13 | Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens |
AU4831401A AU4831401A (en) | 2000-02-18 | 2001-02-13 | TH1 inducing natural adjuvant for heterologous antigens |
US10/222,100 US6936263B2 (en) | 2000-02-18 | 2002-08-16 | Th1 inducing natural adjuvant for heterologous antigens |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00200589.0 | 2000-02-18 | ||
EP00200589 | 2000-02-18 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/222,100 Continuation US6936263B2 (en) | 2000-02-18 | 2002-08-16 | Th1 inducing natural adjuvant for heterologous antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001060404A2 WO2001060404A2 (en) | 2001-08-23 |
WO2001060404A3 true WO2001060404A3 (en) | 2002-01-10 |
Family
ID=8171051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/001673 WO2001060404A2 (en) | 2000-02-18 | 2001-02-13 | Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens |
Country Status (7)
Country | Link |
---|---|
US (1) | US6936263B2 (en) |
EP (1) | EP1255562B1 (en) |
AT (1) | ATE383871T1 (en) |
AU (2) | AU4831401A (en) |
CA (1) | CA2400495A1 (en) |
DE (1) | DE60132427D1 (en) |
WO (1) | WO2001060404A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060404A2 (en) | 2000-02-18 | 2001-08-23 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens |
US20030232055A1 (en) * | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
US20030175287A1 (en) * | 2001-01-03 | 2003-09-18 | Yale University | Innate immune system-directed vaccines |
EP1461085A2 (en) * | 2002-01-03 | 2004-09-29 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Immunoconjugates useful for treatment of tumours |
CN101151280A (en) * | 2005-02-08 | 2008-03-26 | 昆士兰医学研究学院委员会 | Immunogenic molecules |
ES2555544T3 (en) * | 2006-03-07 | 2016-01-04 | Vaxinnate Corporation | Compositions that include hemagglutinin, preparation methods and methods of use thereof |
US7833776B2 (en) | 2007-12-12 | 2010-11-16 | National Health Research Institutes | Lipidating sequences and use thereof for producing lipidated proteins in E. coli |
US8466259B2 (en) * | 2007-12-07 | 2013-06-18 | National Health Research Institutes | Adjuvants |
TWI376385B (en) * | 2007-12-07 | 2012-11-11 | Nat Health Research Institutes | Production of lipidated proteins in e. coli |
WO2009128951A2 (en) | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Compositions of respiratory synctial virus proteins and methods of use |
US8287880B2 (en) | 2009-06-02 | 2012-10-16 | National Health Research Institutes | Lipidated vaccine against dengue virus infection |
WO2010148496A1 (en) * | 2009-06-22 | 2010-12-29 | National Health Research Institutes | Lipidated tumor- associated antigens and immunotherapeutic compositions |
TWI507413B (en) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | Lipidated polyepitope vaccines |
TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
CN113150171B (en) * | 2021-04-25 | 2023-05-16 | 中国农业科学院兰州兽医研究所 | African swine fever virus recombinant protein containing intramolecular adjuvant, expression vector and application |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3829616C2 (en) * | 1988-09-01 | 1996-08-29 | Behringwerke Ag | Lipoprotein I (OMPI) from Pseudomonas aeruginosa |
FR2708622B1 (en) * | 1993-08-02 | 1997-04-18 | Raymond Hamers | Recombinant vector containing a sequence of a structural lipoprotein gene for the expression of nucleotide sequences. |
EP0717106B1 (en) * | 1994-12-16 | 2000-03-15 | Chiron Behring Gmbh & Co. | Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins |
AU6280596A (en) * | 1995-06-15 | 1997-01-15 | University Of Victoria Innovation And Development Corporation | Mycobacterium tuberculosis dna sequences encoding immunostimlatory peptides |
US6607731B1 (en) * | 1995-09-22 | 2003-08-19 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
US6613337B1 (en) * | 1997-02-12 | 2003-09-02 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
US6638517B2 (en) * | 1995-09-22 | 2003-10-28 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
US6537552B1 (en) * | 1999-10-19 | 2003-03-25 | Iowa State University Research Foundation | Vaccine adjuvant |
WO2001060404A2 (en) * | 2000-02-18 | 2001-08-23 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens |
-
2001
- 2001-02-13 WO PCT/EP2001/001673 patent/WO2001060404A2/en active IP Right Grant
- 2001-02-13 AU AU4831401A patent/AU4831401A/en active Pending
- 2001-02-13 EP EP01921281A patent/EP1255562B1/en not_active Expired - Lifetime
- 2001-02-13 DE DE60132427T patent/DE60132427D1/en not_active Expired - Lifetime
- 2001-02-13 AU AU2001248314A patent/AU2001248314B2/en not_active Ceased
- 2001-02-13 CA CA002400495A patent/CA2400495A1/en not_active Abandoned
- 2001-02-13 AT AT01921281T patent/ATE383871T1/en not_active IP Right Cessation
-
2002
- 2002-08-16 US US10/222,100 patent/US6936263B2/en not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
CORNELIS P ET AL: "DEVELOPMENT OF NEW CLONING VECTORS FOR THE PRODUCTION OF IMMUNOGENIC OUTER MEMBRANE FUSION PROTEINS IN ESCHERICHIA COLI", BIOTECHNOLOGY,GB,BUTTERWORTHS, LONDON, vol. 14, no. 2, 1 February 1996 (1996-02-01), pages 203 - 208, XP000651289, ISSN: 0740-7378 * |
COTE-SIERRA J ET AL: "A new membrane-bound OprI lipoprotein expression vector - High production of heterologous fusion proteins in Gram (-) bacteria and the implications for oral vaccination", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES,GB,ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 221, no. 1, 9 October 1998 (1998-10-09), pages 25 - 34, XP004143138, ISSN: 0378-1119 * |
INFANTE-DUARTE, CARMEN ET AL: "Lipopeptides of Borrelia burgdorferi outer surface proteins induce Th1 phenotype development in alpha-beta T-cell receptor transgenic mice.", INFECTION AND IMMUNITY, (1997) VOL. 65, NO. 10, PP. 4094-4099., XP000916030 * |
JONGERT, E. (1) ET AL: "Development of a living bacterial carrier system, based on the lipoprotein I of Pseudomonas aeruginosa, for oral vaccination against food-and-mouth-disease virus.", RESEARCH IN IMMUNOLOGY, (JAN., 1998) VOL. 149, NO. 1, PP. 97. MEETING INFO.: EUROCONFERENCE ON NEW TRENDS IN VACCINE RESEARCH AND DEVELOPMENT: ADJUVANTS, DELIVERY SYSTEMS AND ANTIGEN FORMULATIONS PARIS, FRANCE FEBRUARY 26-28, 1998, XP001013024 * |
NABORS G S ET AL: "SWITCH FROM A TYPE 2 TO A TYPE 1 T HELPER CELL RESPONSE AND CURE OF ESTABLISHED LEISHMANIA MAJOR INFECTION IN MICE IS INDUCED BY COMBINED THERAPY WITH INTERLEUKIN 12 AND PENTOSTAM", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, 1 April 1995 (1995-04-01), pages 3142 - 3146, XP002060391, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
DE60132427D1 (en) | 2008-03-06 |
AU4831401A (en) | 2001-08-27 |
CA2400495A1 (en) | 2001-08-23 |
AU2001248314B2 (en) | 2004-08-19 |
US6936263B2 (en) | 2005-08-30 |
EP1255562A2 (en) | 2002-11-13 |
EP1255562B1 (en) | 2008-01-16 |
US20030059439A1 (en) | 2003-03-27 |
WO2001060404A2 (en) | 2001-08-23 |
ATE383871T1 (en) | 2008-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001060404A3 (en) | Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens | |
HK1121382A1 (en) | Adjuvant compositions for enhancing immune responses to polynucleotide- based vaccines | |
AU2001295673A1 (en) | Vaccine composition | |
WO2001060402A3 (en) | Proteosome influenza vaccine | |
HUP0004327A3 (en) | Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions | |
DE69531297D1 (en) | RECOMBINANT PAPILLOMAVIRUS L1 | |
AR014182A1 (en) | COMPOSITIONS OF USEFUL VACCINES FOR THE TREATMENT OR PROFILAXIS OF TUMORS OR INJURIES DUE TO HPV; PROCEDURE TO PREVENT OR TREAT TUMORS INDUCED BY HPV AND PROCEDURE TO PREPARE SUCH COMPOSITIONS | |
AU2151902A (en) | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens | |
AU2001248314A1 (en) | Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens | |
WO2004078099A3 (en) | Compositions and methods for the generation of protective immune response against malaria | |
WO2000006198A3 (en) | Adjuvant comprising pulmonary surfactant | |
WO1998001558A3 (en) | Protein and peptide vaccines for inducing mucosal immunity | |
ATE185073T1 (en) | VACCINE PREPARATIONS | |
EP1131338A4 (en) | Method for the production of purified invasin protein and use thereof | |
HK1025220A1 (en) | Novel saponin compositions and uses thereof | |
WO2003050135A3 (en) | Use a parapox b2l protein to modify immune responses to administered antigens | |
WO2001035993A3 (en) | Compositions and methods for stimulating an immune response against infectious agents | |
WO2002085409A3 (en) | Methods and compositions for inducing an immune response to an antigen | |
WO2002072622A3 (en) | Vaccine antigens against infection by chlamydia trachomatis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001248314 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001921281 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2400495 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10222100 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001921281 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001248314 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001921281 Country of ref document: EP |